Aberdeen Group plc Buys 7,184,457 Shares of Immunic, Inc. $IMUX

Key Points

• Aberdeen Group plc significantly increased its stake in Immunic, Inc. by 678.1%, acquiring 7,184,457 shares during the second quarter, bringing its total ownership to approximately 8.60% of the company.
• Despite a recent increase in institutional ownership, Immunic received a "sell (d-)" rating from Weiss Ratings, while HC Wainwright and D. Boral Capital maintained a "buy" rating with target prices of $10.00.
• Immunic's stock recently traded at $0.82, showing a decline of 2.6%, with analysts forecasting a negative EPS of -0.94 for the current year.

Aberdeen Group plc raised its stake in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 678.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,243,941 shares of the company's stock after acquiring an additional 7,184,457 shares during the period. Aberdeen Group plc owned approximately 8.60% of Immunic worth $5,750,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of IMUX. Jane Street Group LLC increased its holdings in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after acquiring an additional 152,726 shares during the last quarter. 683 Capital Management LLC increased its holdings in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Focus Partners Wealth increased its holdings in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after acquiring an additional 415,104 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IMUX has been the topic of a number of research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Immunic in a report on Wednesday, October 8th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Immunic in a report on Friday, September 26th. D. Boral Capital restated a "buy" rating and issued a $10.00 target price on shares of Immunic in a report on Thursday, September 25th. Finally, Chardan Capital initiated coverage on shares of Immunic in a report on Monday, September 29th. They issued a "buy" rating and a $13.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.

Immunic Trading Down 2.6%

IMUX stock opened at $0.82 on Friday. Immunic, Inc. has a 12 month low of $0.56 and a 12 month high of $1.73. The company has a 50-day moving average price of $0.87 and a 200 day moving average price of $0.90. The stock has a market cap of $80.49 million, a PE ratio of -0.87 and a beta of 1.56.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). Sell-side analysts forecast that Immunic, Inc. will post -0.94 EPS for the current year.

Immunic Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Want to see what other hedge funds are holding IMUX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunic, Inc. (NASDAQ:IMUX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.